These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37958662)

  • 1. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
    Fabro F; Kers TV; Feller KJ; Beerens C; Ntafoulis I; Idbaih A; Verreault M; Connor K; Biswas A; Salvucci M; Prehn JHM; Byrne AT; O'Farrell AC; Lambrechts D; Dilcan G; Lodi F; Arijs I; Kremer A; Tching Chi Yen R; Chien MP; Lamfers MLM; Leenstra S
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
    Ma J; Wang Z; Chen CC; Li M
    Oncotarget; 2023 May; 14():483-484. PubMed ID: 37204260
    [No Abstract]   [Full Text] [Related]  

  • 4. MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
    Cheng ZX; Yin WB; Wang ZY
    Int J Mol Med; 2017 Nov; 40(5):1307-1314. PubMed ID: 28901390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
    Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
    Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
    Ntafoulis I; Kleijn A; Ju J; Jimenez-Cowell K; Fabro F; Klein M; Chi Yen RT; Balvers RK; Li Y; Stubbs AP; Kers TV; Kros JM; Lawler SE; Beerepoot LV; Kremer A; Idbaih A; Verreault M; Byrne AT; O'Farrell AC; Connor K; Biswas A; Salvucci M; Prehn JHM; Lambrechts D; Dilcan G; Lodi F; Arijs I; van den Bent MJ; Dirven CMF; Leenstra S; ; Lamfers MLM
    Br J Cancer; 2023 Oct; 129(8):1327-1338. PubMed ID: 37620410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
    Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
    Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.
    Riganti C; Salaroglio IC; Caldera V; Campia I; Kopecka J; Mellai M; Annovazzi L; Bosia A; Ghigo D; Schiffer D
    Neuro Oncol; 2013 Nov; 15(11):1502-17. PubMed ID: 23897632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
    J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma.
    Zhao C; Gao Y; Guo R; Li H; Yang B
    Invest New Drugs; 2020 Oct; 38(5):1227-1235. PubMed ID: 31823158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
    Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F
    Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
    Yip S; Miao J; Cahill DP; Iafrate AJ; Aldape K; Nutt CL; Louis DN
    Clin Cancer Res; 2009 Jul; 15(14):4622-9. PubMed ID: 19584161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond
    Rao V; Kumar G; Vibhavari RJA; Nandakumar K; Thorat ND; Chamallamudi MR; Kumar N
    CNS Neurol Disord Drug Targets; 2023; 22(6):817-831. PubMed ID: 35379142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
    Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
    Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
    Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S
    Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
    Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
    Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
    Xu H; Jin J; Chen Y; Wu G; Zhu H; Wang Q; Wang J; Li S; Grigore FN; Ma J; Chen CC; Lan Q; Li M
    Oncogene; 2022 Jul; 41(31):3876-3885. PubMed ID: 35780181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.